Report on Veterinary Drug Product – Vetoryl

*Note: Vetoryl was reviewed under the Pre-2010 Guidelines as it was first sold prior to 2010.

Publication of the MAPP is for information only and should not be construed as indicating that the introductory National Average Transaction Price (which represents the average price for each dosage form, strength and package size in which the medicine is sold by the patentee to each class of customer in each province and territory) is at that level. Please be aware that information provided at the time of the original price review may not reflect the current therapeutic alternatives at the time of subsequent request and as such, Board Staff is not bound to apply the same comparators and dosage regimens if subsequent scientific information substantiates that changes would be appropriate.